{"product_id":"staar-marketing-mix","title":"STAAR Surgical Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuilt for Strategy. Ready in Minutes.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how STAAR Surgical’s product innovation, targeted pricing, distribution through specialist channels, and clinical-focused promotions combine to drive adoption in ophthalmic markets. This concise 4Ps snapshot highlights competitive strengths and gaps, then directs you to the full, editable Marketing Mix Analysis for deeper data, strategic recommendations, and ready-to-use slides. Purchase the complete report to save research time and apply proven tactics immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEVO\/Visian ICL portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSTAAR’s core offering is the EVO\/Visian ICL family of implantable collamer lenses that correct myopia, hyperopia and astigmatism via intraocular implantation. The EVO\/Visian ICL is positioned as a premium, reversible alternative to laser vision correction emphasizing high-quality optics and minimal induced dry eye. Marketing highlights reversibility, stable refractive outcomes and patient suitability when corneal ablation is contraindicated.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eToric and high-range corrections\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eToric ICLs correct astigmatism alongside spherical errors, expanding candidacy beyond pure myopes. High-diopter options reach patients outside typical laser ranges, enabling treatment of extreme refractive errors. This breadth lets clinics manage complex refractive profiles and increases case mix. It differentiates STAAR by refractive breadth and clinical versatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollamer material \u0026amp; lens design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProprietary Collamer blends collagen copolymer for high biocompatibility and optical clarity, minimizing tissue response while maintaining refractive stability. Lens geometry promotes predictable, stable vaulting over the crystalline lens to reduce cataract risk and refractive surprises. Central port design (0.36 mm KS-Aquaport) supports physiological aqueous flow, improving safety and IOP predictability. Performance targets safety, predictability, and superior visual quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCataract IOLs and supporting optics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSTAAR also offers cataract IOLs and supporting optics that complement its refractive ICL portfolio, enabling surgeons to manage refractive and cataract cases across the patient vision-care journey. With over 20 million cataract surgeries globally annually (WHO range 2022–24) and a global IOL market ~3.7 billion USD in 2024, this diversification hedges procedural mix and broadens account relevance while reinforcing STAAR brand equity in premium intraocular optics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProduct role: Cataract IOLs complement ICLs\u003c\/li\u003e\n\u003cli\u003eMarket context: \u0026gt;20M surgeries\/yr (WHO 2022–24)\u003c\/li\u003e\n\u003cli\u003eMarket size: ~3.7B USD IOL market (2024)\u003c\/li\u003e\n\u003cli\u003eStrategic benefit: diversifies revenue base, strengthens premium optics positioning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDelivery systems and customization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSingle-use injectors provide controlled Visian ICL insertion and reduce contamination risk, supporting predictable placement; lenses are sized using biometric inputs such as white-to-white and anterior chamber depth to optimize vault. Custom sterile packaging and procedure customization improve OR efficiency and visual outcomes; STAAR has delivered over 1 million implants worldwide by 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eControlled insertion via single-use injectors\u003c\/li\u003e\n\u003cli\u003eBiometric sizing (WTW, ACD) to optimize vault\u003c\/li\u003e\n\u003cli\u003eSterile, customized packaging for surgical efficiency\u003c\/li\u003e\n\u003cli\u003eSystem-level value beyond implant\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEVO\/Visian ICLs: reversible, biocompatible vision correction with OR-ready injectors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSTAAR’s EVO\/Visian ICL family delivers premium, reversible correction for myopia, hyperopia and astigmatism with Collamer biocompatibility, central port safety and predictable vaulting. Single-use injectors, biometric sizing and sterile packaging support OR efficiency and outcomes. Portfolio includes cataract IOLs, diversifying exposure amid a ~3.7B USD IOL market and \u0026gt;20M cataract surgeries\/yr; \u0026gt;1M ICLs implanted by 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eSource (yr)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eICL implants\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,000,000\u003c\/td\u003e\n\u003ctd\u003eSTAAR (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIOL market\u003c\/td\u003e\n\u003ctd\u003e~3.7B USD\u003c\/td\u003e\n\u003ctd\u003eMarket data (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCataract surgeries\/yr\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;20,000,000\u003c\/td\u003e\n\u003ctd\u003eWHO (2022–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into STAAR Surgical’s Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground recommendations for managers, consultants, and marketers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses STAAR Surgical's 4P marketing analysis into a concise, actionable snapshot that relieves stakeholder pain by clarifying pricing, product positioning, promotion channels, and placement strategy for faster decisions and cross‑functional alignment. Ideal for leadership briefings, rapid strategy sessions, and plug‑and‑play inclusion in decks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgeon-only clinical channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSurgeon-only clinical channel supplies ICLs exclusively to board-certified ophthalmic surgeons and refractive centers, targeting practices equipped for intraocular procedures. Direct engagement with clinics and surgeon training supports proper indication and patient selection, underpinning safety and outcomes. The channel has supported hundreds of thousands of EVO\/ICl procedures globally, preserving product integrity and clinical results.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal distributors and direct sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSTAAR Surgical uses a hybrid go-to-market model with direct sales in key markets and regional distributors covering 75+ countries. Local partners handle in-country logistics, regulatory compliance, and service, shortening time-to-patient and reducing operational complexity. Coverage spans North America, EMEA, APAC, and Latin America, balancing broad reach with specialist local support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvailability is tied to jurisdictional regulatory approvals, notably FDA clearance for the EVO ICL in 2022, with STAAR's portfolio now sold in 75+ countries. Market entry is sequenced via regulatory approval, local reimbursement pathways and KOL adoption to drive uptake. Labeling and surgeon training are localized to local standards and languages. This framework supports compliant, consistent clinical use and broader adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMade-to-order and inventory hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMade-to-order sizing for STAAR Surgical products links SKUs to patient biometrics, so many lenses are built-to-order and tracked by batch; regional inventory hubs and demand forecasting shorten delivery for common sizes and support OR schedules. Sterile handling and tight shelf-life controls are standard; cold-chain is generally not required.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuilt-to-order SKUs tied to biometric data\u003c\/li\u003e\n\u003cli\u003eRegional hubs + forecasting reduce lead times\u003c\/li\u003e\n\u003cli\u003eSterile handling; strict shelf-life management\u003c\/li\u003e\n\u003cli\u003eFulfillment aligned to OR timing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-theater training and service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpin-theater training and service by staar surgical field specialists staa supports onboarding case observation staff leveraging visian icl fda approval in to boost clinical confidence. practice development tools improve patient flow conversion technical support reduces variability risk while nearby teams increase loyalty reorder frequency.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eField specialists: onsite onboarding \u0026amp; case support\u003c\/li\u003e\n\u003cli\u003ePractice resources: higher conversion, smoother flow\u003c\/li\u003e\n\u003cli\u003eTechnical support: fewer complications, consistency\u003c\/li\u003e\n\u003cli\u003eService proximity: increased loyalty and reorders\u003c\/li\u003e\n\u003c\/pin-theater\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgeon-channel ICL supply: built-to-order biometrics, regional hubs, FDA cleared (2018, 2022)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSurgeon-only clinical channel supplies ICLs to board-certified ophthalmic surgeons and refractive centers, supported by direct sales in key markets and distributors across 75+ countries. Built-to-order SKUs tied to biometrics use regional hubs and forecasting to shorten lead times for hundreds of thousands of global EVO\/ICL procedures. FDA clearances: EVO 2022; Visian ICL 2018.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic reach\u003c\/td\u003e\n\u003ctd\u003e75+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcedures (cumulative)\u003c\/td\u003e\n\u003ctd\u003eHundreds of thousands\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGo‑to‑market\u003c\/td\u003e\n\u003ctd\u003eDirect + regional distributors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey FDA dates\u003c\/td\u003e\n\u003ctd\u003eEVO 2022; Visian 2018\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eSTAAR Surgical 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual STAAR Surgical 4P's Marketing Mix Analysis you'll receive instantly after purchase—no surprises. This same comprehensive, editable document covers Product, Price, Place and Promotion and is fully complete and ready to use. Download the exact file shown here immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eromotion\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKOL advocacy and surgeon education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKOL advocacy programs at STAAR Surgical (NASDAQ: STAA) deploy leading surgeons for technique training and peer-to-peer learning to accelerate Visian ICL adoption. Wet labs, webinars and proctorships build surgeon confidence and reinforce best practices. Peer-reviewed case studies and outcomes data underpin credibility and drive faster uptake among clinicians.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical evidence and publications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePeer-reviewed studies document safety, efficacy and high patient satisfaction for STAAR ICL procedures. Longitudinal data, including follow-ups up to 10 years, support durability of visual outcomes. Published evidence is repurposed across sales tools and regulatory dossiers worldwide. This science-first messaging clearly differentiates from elective laser-only options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient demand generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDigital campaigns and clinic co-marketing raise awareness of ICL benefits, driving measurable traffic and industry-average CTRs of roughly 2–5%. Messaging emphasizes quality of vision, reversibility and suitability for dry-eye or thin corneas; STAAR reported over 1 million EVO ICL implants worldwide (company milestone). Testimonials and before\/after stories aid consideration and feed tools that drive qualified inquiries to partner clinics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital tools and practice enablement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCalculator apps, sizing guides and workflow templates reduce consult time and errors, standardizing assessments and enabling higher throughput; co-branded materials and clinic ROI models demonstrate payback to administrators, while CRM-driven lead nurture and targeted content boost conversion and drive utilization per account.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCalculator apps: faster, standardized consults\u003c\/li\u003e\n\u003cli\u003eSizing guides: fewer follow-ups\u003c\/li\u003e\n\u003cli\u003eROI models: clinic buy-in\u003c\/li\u003e\n\u003cli\u003eCRM + nurture: higher conversion, increased utilization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConferences and strategic partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePresence at ASCRS, ESCRS, AAO and regional meetings sustains STAAR Surgical visibility, with AAO drawing roughly 18,000–20,000 attendees in 2024; partnerships with refractive networks and premium cataract centers broaden reach and referral pipelines. Live surgery events and symposia showcase technique and reinforce brand leadership through surgeon education and device adoption.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConference reach: AAO ~18k–20k (2024)\u003c\/li\u003e\n\u003cli\u003ePartnerships: refractive networks, premium cataract centers\u003c\/li\u003e\n\u003cli\u003eActivation: live surgery, symposia\u003c\/li\u003e\n\u003cli\u003eOutcome: sustained visibility, increased adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKOL-led digital campaigns + 10-year evidence drive \u0026gt;1,000,000 implant adoptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSTAAR promotion blends KOL programs, peer-reviewed evidence and digital\/co‑marketing to drive Visian ICL adoption; company milestone: \u0026gt;1,000,000 EVO ICL implants. Campaigns deliver ~2–5% CTR, conference reach AAO ~18,000–20,000 (2024) and long-term data to 10 years underpin trust. Tools (calculator, ROI models, CRM) shorten consults and boost clinic conversion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEVO implants\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,000,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCTR\u003c\/td\u003e\n\u003ctd\u003e2–5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAAO 2024 reach\u003c\/td\u003e\n\u003ctd\u003e18,000–20,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFollow-up data\u003c\/td\u003e\n\u003ctd\u003eUp to 10 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003erice\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremium value pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePricing reflects a premium, technology-driven alternative to laser surgery, typically $3,500–6,500 per eye in clinic listings. Value is tied to superior optical quality, reversibility, and surgeon support, commanding a 20–40% price premium versus LASIK. Positioning targets patients willing to invest in superior vision outcomes, with clinics capturing margin through premium-service bundling such as warranties and enhanced follow-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTiered by lens type and features\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSKU pricing is tiered by sphere, toric, and specialized ICLs, with industry 2024 average lens prices roughly $2,000–$4,500 per eye; toric and specialty lenses commonly command a 20–40% premium over basic sphere SKUs. Feature tiers map to perceived clinical benefit (astigmatism correction, enhanced optics), and transparent tiered lists streamline clinic quoting and patient pricing discussions. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVolume and loyalty incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAccounts access tiered discounts through formal volume commitments and growth-based pricing, while bundles pairing ICLs with injectors and clinical training materially improve net pricing and lower adoption barriers. Structured rebates tied to utilization reward consistent procedure volumes, strengthening customer lock-in and incentivizing standardization on the STAAR platform. This approach drives predictable revenue per account and simplifies procurement for high-volume surgical centers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient bundles and financing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eClinics typically bundle lens, surgeon fee, facility and follow-ups into a single price to simplify consults; industry pricing in 2024 commonly ranged about $4,000–6,000 per eye for phakic IOL procedures. Third-party financing (patient loans\/healthcare credit) makes out-of-pocket costs manageable and transparently packaged offers reduce decision friction, expanding the addressable patient pool.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBundle: lens + surgeon + facility + follow-ups\u003c\/li\u003e\n\u003cli\u003eTypical 2024 price: $4,000–6,000 per eye\u003c\/li\u003e\n\u003cli\u003eFinancing: lowers upfront barrier, increases conversions\u003c\/li\u003e\n\u003cli\u003eTransparent packages: faster consult decisions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional and market-adjusted pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegional and market-adjusted pricing for STAAR Surgical (NASDAQ: STAA) varies by country, currency and competitive landscape, factoring regulatory costs, taxes and reimbursement nuances to protect margins. Guardrails preserve global brand equity while enabling local competitiveness; pricing is reviewed periodically to reflect inflation and demand shifts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNASDAQ: STAA\u003c\/li\u003e\n\u003cli\u003eEU VAT ~21% impacts end price\u003c\/li\u003e\n\u003cli\u003eLocal reimbursement drives adoption\u003c\/li\u003e\n\u003cli\u003ePeriodic CPI-linked reviews\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhakic IOLs premium: \u003cstrong\u003e$4k-6k\u003c\/strong\u003e\/eye, \u003cstrong\u003e20-40%\u003c\/strong\u003e vs LASIK\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSTAAR pricing positions phakic IOLs as premium, typically $3,500–6,500 per eye (2024 clinic range $4,000–6,000), reflecting a 20–40% premium vs LASIK. SKU tiers (sphere, toric, specialty) price roughly $2,000–4,500 per lens; toric\/specialty add 20–40%. Bundles + financing raise conversions and protect margins; regional VAT\/reimbursement materially shifts net patient price.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eNote\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinic price\/eye\u003c\/td\u003e\n\u003ctd\u003e$4,000–6,000\u003c\/td\u003e\n\u003ctd\u003e2024 market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLens SKU\u003c\/td\u003e\n\u003ctd\u003e$2,000–4,500\u003c\/td\u003e\n\u003ctd\u003etoric +20–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePremium vs LASIK\u003c\/td\u003e\n\u003ctd\u003e20–40%\u003c\/td\u003e\n\u003ctd\u003equality\/reversibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU VAT\u003c\/td\u003e\n\u003ctd\u003e~21%\u003c\/td\u003e\n\u003ctd\u003eaffects end price\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098202739036,"sku":"staar-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/staar-marketing-mix.png?v=1781806437","url":"https:\/\/pestel-analysis.com\/products\/staar-marketing-mix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}